Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Since 2014 several direct-acting antivirals (DAAs) have been made available, allowing interferon-free antiviral treatments with high sustained virological response rates. Side effects are, however, a real challenge during treatment. Sarkar et al. recently published a case of colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C. We report the case of a patient with no prior history of inflammatory bowel disease, who developed significant bloody diarrhea within 3 weeks of sofosbuvir/simeprevir/ribavirin initiation. Colonoscopy and biopsy suggested a drug-induced colitis.
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy. izzo.ilaria@hotmail.it.
Ilaria
http://orcid.org/0000-0001-9611-6160
I
Izzo
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Paola
P
Zanotti
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Claudia
C
Chirico
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Salvatore
S
Casari
Spedali Civili General Hospital, Pathology Institute, Brescia, Italy.
Vincenzo
V
Villanacci
Spedali Civili General Hospital, Pathology Institute, Brescia, Italy.
Marianna
M
Salemme
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Luciano
L
Biasi
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Elena
E
Festa
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Francesco
F
Castelli
D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003092:Colitis / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D000069616:Simeprevir / Q000009:adverse effects* / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D012254:Ribavirin; D000069616:Simeprevir; D000069474:Sofosbuvir
Drug-induced colitis; HCV; New direct-acting antiviral agents